{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pulmonary-embolism/prescribing-information/parenteral-anticoagulants/","result":{"pageContext":{"chapter":{"id":"8b812684-b06c-50e2-86d7-f012b792c674","slug":"parenteral-anticoagulants","fullItemName":"Parenteral anticoagulants","depth":2,"htmlHeader":"<!-- begin field d0d2ecc2-3310-4270-9531-ab8e00ae5abb --><h2>Parenteral anticoagulants</h2><!-- end field d0d2ecc2-3310-4270-9531-ab8e00ae5abb -->","summary":"","htmlStringContent":"<!-- begin item 3071e538-2971-43b4-ad44-ab8e00ae5a5d --><!-- begin field 3f10d414-48a8-43b3-8769-ab8e00ae5abb --><ul><li>The parenteral anticoagulants licensed for the treatment of pulmonary embolism are [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Joint Formulary Committee, 2020</a>]: <ul><li>Low molecular weight heparins (dalteparin, enoxaparin, and tinzaparin).</li><li>Fondaparinux, a synthetic pentasaccharide that inhibits activated factor X.</li></ul></li></ul><!-- end field 3f10d414-48a8-43b3-8769-ab8e00ae5abb --><!-- end item 3071e538-2971-43b4-ad44-ab8e00ae5a5d -->","topic":{"id":"322088c5-226e-5f2b-9fd2-2e2c0678abc1","topicId":"6b233aab-5318-4abb-96fa-1877e917ef2c","topicName":"Pulmonary embolism","slug":"pulmonary-embolism","lastRevised":"Last revised in October 2020","chapters":[{"id":"7d60ce89-0a3c-5336-a5d4-755eb5bfb2cd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99df9a07-7867-5283-b7c8-4589c8f6e029","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b4da2d8a-f835-512f-b218-660b7fc61806","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c60f44ed-a5f4-566e-8718-a289b4d4e969","slug":"changes","fullItemName":"Changes"},{"id":"42a750f4-f134-55a8-a654-9c23ac2a3bfd","slug":"update","fullItemName":"Update"}]},{"id":"b8001d19-4cf2-5db4-b8b5-f082fbff4fbd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"52656989-9cf4-597c-8118-0fadcb887b21","slug":"goals","fullItemName":"Goals"},{"id":"cdd140ec-bd30-59e9-9777-c921159ea664","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c32413cc-9382-5aaa-b03b-95ed29a1b360","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c1a308a6-aa46-578f-98f1-ed7872474fb4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1629cec2-329a-5273-a313-15a0783d5b22","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d4860e1f-9b8b-5f49-bdb5-fb068af327ab","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9e6802a1-b9c3-5fa9-b632-ef9712c1724b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"588bb6e5-794e-52df-9953-d91254204285","slug":"definition","fullItemName":"Definition"},{"id":"e2fbb90b-8419-52d9-bfd2-a9eab621be3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad38abd5-7668-59b3-828a-9edd427dbdd5","slug":"pathophysiology","fullItemName":"Pathophysiology"},{"id":"9b45f610-d957-50a3-9e85-019832acd145","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8e279dc8-2394-5073-8866-952291c0eee6","slug":"complications","fullItemName":"Complications"},{"id":"8be5980d-145d-5d9c-b255-f057579ce868","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c07c0850-0c27-58a8-96a8-96051968c076","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1db70c8e-a80c-587a-8e5e-5adf28878587","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"a71fc8ea-c1d7-5be5-a888-41b834fdca93","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f18a5246-939d-51ce-adb5-f6538871345a","fullItemName":"Management","slug":"management","subChapters":[{"id":"42f102a2-ceab-531f-880e-4075895d9c12","slug":"suspected-pulmonary-embolism","fullItemName":"Scenario: Suspected pulmonary embolism"},{"id":"cd66b55b-908e-56dc-811f-db55be20b710","slug":"confirmed-pulmonary-embolism","fullItemName":"Scenario: Confirmed pulmonary embolism"}]},{"id":"6ae8a494-48a2-5d60-b0f8-39dd5e02489b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8b812684-b06c-50e2-86d7-f012b792c674","slug":"parenteral-anticoagulants","fullItemName":"Parenteral anticoagulants"},{"id":"f367e7b5-6b1b-5f42-9d57-a8edab35855f","slug":"oral-anticoagulants","fullItemName":"Oral anticoagulants"}]},{"id":"c1bef62c-2c5a-5588-af53-1a0b4b26d3e3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3941fd8f-10fb-53d4-8dc1-3835ad3ca3e3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"26fc4bf9-2995-5109-9f1e-3ba9ad3dd2dd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f1b2f1f8-81e2-5a3c-b454-2f63f66f6235","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"83fd7f66-6953-54a6-b55f-8d2858a82e97","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bd9e363f-a674-594d-8bb9-8779d385e06a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"20c76427-9b00-5da0-bd68-6486385780f2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"96a22dd0-587f-5051-8263-acea49ba216b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6ae8a494-48a2-5d60-b0f8-39dd5e02489b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"888e4692-268c-5678-80fc-2829417c4a18","slug":"dalteparin","fullItemName":"Dalteparin","depth":3,"htmlHeader":"<!-- begin field 8949d2a8-2f6e-498e-84fa-ab8e00aede61 --><h3>What should I be aware of when prescribing dalteparin?</h3><!-- end field 8949d2a8-2f6e-498e-84fa-ab8e00aede61 -->","summary":"","htmlStringContent":"<!-- begin item e6b62a38-0732-4f5c-9850-ab8e00aede30 --><!-- begin field 0f277336-54c4-40ad-83fb-ab8e00aede61 --><ul><li><strong>Dalteparin should be administered subcutaneously.</strong><ul><li><strong>The recommended doses of dalteparin (single-dose injections) for the treatment of pulmonary embolism are </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">BNF 76, 2018</a>]</strong><strong>:</strong><ul><li>Body weight less than 46 kg — 7500 units once daily.</li><li>Body weight 46–56 kg — 10,000 units once daily.</li><li>Body weight 57–68 kg — 12,500 units once daily.</li><li>Body weight 69–82 kg — 15,000 units once daily.</li><li>Body weight 83 kg and over — 18,000 units once daily.</li></ul></li><li>Treatment should be continued until adequate oral anticoagulation with vitamin K antagonist is established (at least 5 days of combined treatment is usually required).</li></ul></li><li><strong>Dalteparin is contraindicated in </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">ABPI, 2016a</a>]</strong><strong>:</strong><ul><li>People with current (or history of) heparin-induced thrombocytopenia.</li><li>People with:<ul><li>Acute gastroduodenal ulcer.</li><li>Cerebral haemorrhage.</li><li>Known haemorrhagic diathesis (a condition causing a predisposition to bleed) or other active haemorrhage.</li><li>Serious coagulation disorders.</li><li>Acute or sub-acute septic endocarditis.</li><li>Haemorrhagic pericardial effusion and haemorrhagic pleural effusion.</li><li>Injuries to and operations on the central nervous system, eyes, and ears.</li></ul></li><li>People who have suffered a recent (within 3 months) stroke, unless due to systemic emboli.</li><li>Note: the needle shield may contain latex (natural rubber) that may cause severe allergic reactions in individuals with hypersensitivity to latex (natural rubber) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">ABPI, 2020a</a>].</li></ul></li><li><strong>For more detailed information on prescribing dalteparin, </strong>including cautions, adverse effects, drug interactions, and monitoring requirements, see the British National Formulary (<a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"27c3360a-b91f-4d5d-a28f-a96600fbf32a\">BNF</a>) and the relevant Summary of Product Characteristics listed in the electronic Medicines Compendium (eMC) (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"a1a399fc-465b-4a95-b215-a96600fbf34d\">www.medicines.org.uk</a>).</li></ul><!-- end field 0f277336-54c4-40ad-83fb-ab8e00aede61 --><!-- end item e6b62a38-0732-4f5c-9850-ab8e00aede30 -->","subChapters":[]},{"id":"3275fdcd-7031-5b0f-9496-bbb6b40010f0","slug":"enoxaparin","fullItemName":"Enoxaparin","depth":3,"htmlHeader":"<!-- begin field 48f7075f-6b79-4023-af20-ab8e00aeeeb8 --><h3>What should I be aware of when prescribing enoxaparin?</h3><!-- end field 48f7075f-6b79-4023-af20-ab8e00aeeeb8 -->","summary":"","htmlStringContent":"<!-- begin item c13bf0b8-bdeb-4b52-8678-ab8e00aeee91 --><!-- begin field 6fd2381c-8a7a-45ec-927d-ab8e00aeeeb8 --><ul><li><strong>Enoxaparin should be administered subcutaneously.</strong><ul><li><strong>The recommended dose of enoxaparin for the treatment of pulmonary embolism in uncomplicated cases with low risk of recurrence<br>is </strong>1.5 mg per kg every 24 hours until adequate oral anticoagulation is established [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">BNF 76, 2018</a>].</li></ul></li><li><strong>Enoxaparin is contraindicat</strong><strong>ed in </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>People with history of immune-mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies. (Circulating antibodies may persist several years.)</li><li>People with acute bacterial endocarditis.</li><li>People with active clinically significant bleeding and conditions with a high risk of haemorrhage, including:<ul><li>Haemophilia and other haemorrhagic disorders.</li><li>Recent haemorrhagic stroke.</li><li>Gastrointestinal ulcer.</li><li>Malignant neoplasm at high risk of bleeding.</li><li>Recent brain, spinal, or ophthalmic surgery.</li><li>Known or suspected oesophageal varices.</li><li>Arteriovenous malformations, vascular aneurysms, or major intraspinal or intracerebral vascular abnormalities.</li></ul></li><li>People with severe renal impairment (creatinine clearance less than 15 mL per min). Careful clinical monitoring is advised for people with moderate (creatinine clearance 30–50 mL per min) and mild (creatinine clearance 50–80 mL per min) renal impairment.</li></ul></li><li><strong>For more detailed information on prescribing enoxaparin, including cautions, adverse effects, drug interactions, and monitoring requirements, </strong>see the British National Formulary (<a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"27c3360a-b91f-4d5d-a28f-a96600fbf32a\">BNF</a>) and the relevant Summary of Product Characteristics listed in the electronic Medicines Compendium (eMC) (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"a1a399fc-465b-4a95-b215-a96600fbf34d\">www.medicines.org.uk</a>).</li></ul><!-- end field 6fd2381c-8a7a-45ec-927d-ab8e00aeeeb8 --><!-- end item c13bf0b8-bdeb-4b52-8678-ab8e00aeee91 -->","subChapters":[]},{"id":"6398e363-e85c-5b1f-bbf6-384703098266","slug":"tinzaparin","fullItemName":"Tinzaparin","depth":3,"htmlHeader":"<!-- begin field a8670c12-0972-429b-acb9-ab8e00af00fb --><h3>What should I be aware of when prescribing tinzaparin?</h3><!-- end field a8670c12-0972-429b-acb9-ab8e00af00fb -->","summary":"","htmlStringContent":"<!-- begin item 761a3684-1a32-4458-9a89-ab8e00af00d2 --><!-- begin field 28fd9e79-d5cb-42d8-ad6c-ab8e00af00fb --><ul><li><strong>Tinzaparin should be administered subcutaneously.</strong><ul><li><strong>The recommended dose of tinzaparin for the treatment of pulmonary embolism is </strong>175 units per kg once daily until adequate oral anticoagulation is established [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">BNF 76, 2018</a>].</li></ul></li><li><strong>Tinzaparin is contraindicated in people with </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">ABPI, 2018b</a>]</strong><strong>:</strong><ul><li>Current (or history) of heparin-induced thrombocytopenia.</li><li>Active major haemorrhage or conditions predisposing to major haemorrhage. Major haemorrhage is defined as fulfilling any one of these three criteria:<ul><li>Occurs in a critical area or organ (for example intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, intra-uterine, or intramuscular with compartment syndrome).</li><li>Causes a fall in haemoglobin level of 20 g per L (1.24 mmol per L) or more.</li><li>Leads to transfusion of two or more units of whole blood or red blood cells.</li></ul></li><li>Septic endocarditis.</li></ul></li><li><strong>For more detailed information on prescribing tinzaparin, including cautions, adverse effects, drug interactions, and monitoring requirements, </strong>see the British National Formulary (<a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"27c3360a-b91f-4d5d-a28f-a96600fbf32a\">BNF</a>) and the relevant Summary of Product Characteristics listed in the electronic Medicines Compendium (eMC) (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"a1a399fc-465b-4a95-b215-a96600fbf34d\">www.medicines.org.uk</a>).</li></ul><!-- end field 28fd9e79-d5cb-42d8-ad6c-ab8e00af00fb --><!-- end item 761a3684-1a32-4458-9a89-ab8e00af00d2 -->","subChapters":[]},{"id":"6334cea4-35ed-56fe-801b-be3ee6b714e7","slug":"fondaparinux","fullItemName":"Fondaparinux","depth":3,"htmlHeader":"<!-- begin field d92566e9-0edf-4dce-bc68-ab8e00af14ef --><h3>What should I be aware of when prescribing fondaparinux?</h3><!-- end field d92566e9-0edf-4dce-bc68-ab8e00af14ef -->","summary":"","htmlStringContent":"<!-- begin item 69a48cd7-9892-4120-8686-ab8e00af14b7 --><!-- begin field 36aa5157-a7a7-4b74-8473-ab8e00af14ef --><ul><li><strong>Fondaparinux should be administered subcutaneously.</strong><ul><li><strong>The recommended doses of fondaparinux for the treatment of pulmonary embolism are </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">BNF 76, 2018</a>]</strong><strong>:</strong><ul><li>Body weight less than 50 kg — 5 mg every 24 hours.</li><li>Body weight 50–100 kg — 7.5 mg every 24 hours.</li><li>Body weight over 100 kg — 10 mg every 24 hours.</li></ul></li><li>An oral anticoagulant (usually warfarin) is started at the same time as fondaparinux. Fondaparinux should be continued for at least 5 days and until international normalized ratio (INR) is 2 or more for at least 24 hours.</li></ul></li><li><strong>Fondaparinux is contraindicated in people with </strong><strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">ABPI, 2018c</a>]</strong> <strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">BNF 76, 2018</a>]</strong><strong>:</strong><ul><li>Active clinically significant bleeding.</li><li>Acute bacterial endocarditis.</li><li>Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 30 mL per minute per 1.73 m<sup>2</sup>). It should be used with caution in moderate renal impairment (eGFR 30–50 mL per minute per 1.73 m<sup>2</sup>).</li></ul></li><li><strong>For more detailed information on prescribing fondaparinux, including cautions, adverse effects, drug interactions, and monitoring requirements, </strong>see the British National Formulary (<a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"27c3360a-b91f-4d5d-a28f-a96600fbf32a\">BNF</a>) and the relevant Summary of Product Characteristics listed in the electronic Medicines Compendium (eMC) (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"a1a399fc-465b-4a95-b215-a96600fbf34d\">www.medicines.org.uk</a>).</li></ul><!-- end field 36aa5157-a7a7-4b74-8473-ab8e00af14ef --><!-- end item 69a48cd7-9892-4120-8686-ab8e00af14b7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}